ADVERTISEMENT
Glenmark's favipiravir version shows promise in late-stage Covid-19 trial
Reuters
Last Updated IST
Representative image. Credits: Reuters Photo
Representative image. Credits: Reuters Photo

India's Glenmark Pharmaceuticals Ltd said on Wednesday its version of anti-flu drug favipiravir showed promise in a late-stage study of 150 patients with mild to moderate coronavirus infection.

About 70% of patients being treated by FabiFlu achieved "clinical cure" by the fourth day of the study, compared with about 45% seen in the group treated with standard supportive care, the company said in a statement

ADVERTISEMENT
ADVERTISEMENT
(Published 22 July 2020, 17:38 IST)